Immunovant’s Roivant parent disclosed early Phase 2b open-label results for IMVT-1402, a next-generation FcRn inhibitor in difficult-to-treat rheumatoid arthritis. The company said 16-week data showed “really great” response rates across ACR20/50/70 assessments in patients who had failed at least two prior advanced therapies, with the program continuing and next steps including discussions with the FDA.